<DOC>
	<DOC>NCT01069757</DOC>
	<brief_summary>This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in patients with advanced/recurrent non-small-cell lung cancer. The pharmacokinetic profile and antitumor activity of ARQ 197 administered alone or in combination with erlotinib will also be determined as secondary endpoints.</brief_summary>
	<brief_title>A Study of ARQ 197 in Combination With Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Voluntary written informed consent for study participation must be obtained A histologically or cytologically confirmed advanced/recurrent nonsmallcell lung cancer History of ≥1 prior chemotherapy regimen (treatment with EGFR tyrosine kinase inhibitors will be counted as one regimen) ECOG PS of 0 or 1 Life expectancy of ≥3 months Anticancer chemotherapy, anticancer therapy with EGFRTKI, hormone therapy, radiotherapy, immunotherapy, other investigational agents or anticancer antibody therapy within 28 days prior to ARQ 197 dose Surgery for cancer within 28 days prior to ARQ 197 dose Active double cancer Known symptomatic brain metastases An intercurrent illness that is uncontrolled (e.g., infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic arrhythmia, interstitial pneumonia) Pregnant or lactating Subjects who wish to have a child and who would not agree to use contraceptive measures</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced/recurrent non-small-cell lung cancer</keyword>
</DOC>